1 coated tablet contains 5 mg.
4,4'-diacetoxy-diphenyl-(pyridyl-2)-methane (= bisacodyl).
Excipients/Inactive Ingredients: lactose
monohydrate, maize starch dried, starch soluble, glycerol, magnesium
stearate, sucrose (saccharose), talc, acacia, titanium dioxide,
methacrylic acid-methyl methacrylate copolymer (1:1) and methacrylic
acid-methyl methacrylate copolymer (1:2), castor oil, macrogol 6000,
ferric oxide yellow (E172), beeswax white, carnauba wax, shellac.
Pharmacology: As a laxative that acts on the colon,
bisacodyl specifically stimulates the natural evacuation process in the
lower region of the gastrointestinal tract. Therefore, bisacodyl is
ineffective in altering the digestion or absorption of calories or
essential nutrients in the small intestine.
Bisacodyl (Dulcolax) is a locally acting laxative from the diphenylmethane derivatives group.
As a contact laxative, bisacodyl stimulates peristalsis of the colon and
promotes accumulation of water in the colonic lumen which leads to
stimulation of defecation, reduction of transit time and softening of
The laxative effect of Bisacodyl (Dulcolax) occurs upon contact with the
colonic mucosa where it stimulates the sensory nerve endings that
results to increased peristaltic contractions of the large intestine to
produce soft well-formed stools.
This results in a stimulation of
defecation, reduction of transit time, and a softening of the stool. It
is a reversible reaction wherein colonic function would return to its
normal condition after defecation occurs.
The tablets usually exert a laxative effect within 6-12 hours after
intake. The suppositories usually take effect in about 20 minutes (range
10 to 30 minutes); in some cases, it occurs 45 minutes after
Bisacodyl (Dulcolax) is indicated in patients suffering from constipation and for preparation of diagnostic procedures, in pre- and post-operative treatment and in conditions which require defecation to be facilitated.
Unless otherwise prescribed by the physician, the following dosages are recommended: See Table 1.
Click on icon to see table/diagram/image
It is recommended to start with the lowest dose. The dose may be
adjusted up to the maximum recommended dose to produce regular stools.
The maximum daily dose should not be exceeded. (See Table 2.)
Click on icon to see table/diagram/image
The maximum daily dose should not be exceeded.
Children aged 10 years or younger with chronic or persistent
constipation should only be treated under the guidance of a physician.
It is recommended to take the enteric coated tablets at night to promote bowel movement the following morning.
They should be swallowed whole with an adequate amount of fluid.
The coated tablets should not be taken together with products reducing
the acidity of the upper gastrointestinal tract, such as milk, antacids
or proton pump inhibitors, in order not to prematurely dissolve the
Suppositories should be unwrapped and inserted into the rectum, pointed end first.
For preparation of diagnostic procedures, in pre- and post-operative
treatment and in medical conditions which require defecation to be
facilitated, Bisacodyl (Dulcolax) should be used under medical
Bisacodyl (Dulcolax) coated tablets should be combined with the
suppositories in order to achieve complete evacuation of the intestine.
(See Table 3.)
Click on icon to see table/diagram/image
High doses usually result to watery stools (diarrhoea), abdominal cramps and a clinically significant loss of fluid, potassium, and other electrolytes.
Bisacodyl (Dulcolax), as with other laxatives, when taken in chronic overdose may cause chronic diarrhoea, abdominal pain, hypokalaemia, secondary hyperaldosteronism, and renal calculi.
Renal tubular damage, metabolic alkalosis, and muscle weakness secondary to hypokalaemia have also been described in association with chronic laxative abuse.
After ingestion of oral forms of Bisacodyl (Dulcolax), absorption can be minimized or prevented by inducing vomiting or gastric lavage. Replacement of fluids and correction of electrolyte imbalance may be required. This is especially important in the elderly and the young.
Administration of antispasmodics may be of value.
Bisacodyl (Dulcolax) should not be given to patients with ileus, intestinal obstruction, acute abdominal conditions including appendicitis and acute inflammatory bowel diseases and severe abdominal pain associated with nausea and vomiting which may be indicative of severe conditions.
Bisacodyl (Dulcolax) is also contraindicated in severe dehydration and in patients with known hypersensitivity to bisacodyl or any other component of the product.
In cases of rare hereditary conditions that may be incompatible with an excipient of the product, the use of the product is contraindicated.
As with all laxatives, Bisacodyl (Dulcolax) should not be taken on a continuous daily basis or for extended periods without investigating the cause of constipation.
Prolonged excessive use may lead to fluid and electrolyte imbalance and hypokalaemia.
Intestinal loss of fluids can promote dehydration. Symptoms may include thirst and oliguria. In patients suffering from fluid loss where dehydration may be harmful (e.g. renal insufficiency, elderly patients) Bisacodyl (Dulcolax) should be discontinued and only be restarted under medical supervision.
Stimulant laxatives including Bisacodyl (Dulcolax) do not help with weight loss (see Pharmacologicas under Actions).
Patients may experience haematochezia (blood in stool) that is generally mild and self-limiting.
Dizziness and/or syncope have been reported in patients who have taken Bisacodyl (Dulcolax). The details available for these cases suggest that the events would be consistent with defecation syncope (or syncope attributable to straining at stool), or with a vasovagal response to abdominal pain related to the constipation, and not necessarily to the administration of bisacodyl itself.
The use of suppositories may lead to painful sensations and local irritation, especially in patients with anal fissure and ulcerative proctitis.
Patients with rare hereditary conditions of galactose intolerance, e.g. galactosaemia, and fructose intolerance should not take this medicine.
No studies on the effects of Bisacodyl (Dulcolax) on the ability to drive and use machines have been performed.
However, patients should be advised that due to a vasovagal response (e.g., to abdominal spasm) they may experience dizziness and/or syncope. If patients experience abdominal spasm, they should avoid potentially hazardous tasks such as driving or operating machinery.
There are no adequate and well-controlled studies in pregnant women. Long experience has shown no evidence of undesirable or damaging effects during pregnancy.
Nevertheless, as with all drugs, Bisacodyl (Dulcolax) should be taken during pregnancy only on medical advice.
Bisacodyl (Dulcolax) can be used during breast-feeding.
No studies on the effect on human fertility have been conducted.
The most commonly reported adverse reactions during treatment with Bisacodyl (Dulcolax) are abdominal pain and diarrhoea.
The following episodes may occur: Immune system disorders: anaphylactic reactions, angioedema, hypersensitivity.
Metabolism and nutrition disorders: dehydration.
Nervous system disorders: dizziness, syncope.
Dizziness and syncope occurring after taking bisacodyl appear to be consistent with a vasovagal response (e.g., to abdominal spasm, defecation).
Gastrointestinal disorders: abdominal cramps, abdominal pain, diarrhoea, nausea, haematochezia (blood in stool), vomiting, abdominal discomfort, anorectal discomfort, colitis, including ischaemic colitis.
The concomitant use of diuretic and adreno-corticosteroids may increase the risk of electrolyte imbalance if excessive doses of Bisacodyl (Dulcolax) are taken. If so, electrolyte imbalance may increase the sensitivity to cardiac glycosides.
The concomitant use of other laxatives may enhance the gastrointestinal side effects of Bisacodyl (Dulcolax).
Store tablets at temperatures not exceeding 30°C.
A06AB02 - bisacodyl ; Belongs to the class of contact laxatives.